Today’s Research Reports on Trending Tickers: Juno Therapeutics and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, with the Healthcare and Materials contributing most losses. The Dow Jones Industrial Average declined 0.31 percent to close at 24,508.66, while the S&P 500 Index fell 0.41 percent to close at 2,652.01. The Nasdaq Composite Index decreased 0.28 percent to close at 6,856.53.
"This market has been going in lockstep with the progress made in the tax bill," said Art Hogan, chief market strategist at B. Riley FBR. "When you see bumps in the road, you're going to get some volatility."
RDI Initiates Coverage on:
Juno Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=JUNO
Seattle Genetics, Inc.
https://rdinvesting.com/news/?ticker=SGEN
Juno Therapeutics stock moved 6.83% lower Thursday, to close the day at $44.17. The stock recorded a trading volume of 4,361,006 shares, which was above its three months average volume of 2,355,290 shares. In the last year, Juno Therapeutics shares have traded in a range of 17.52 - 63.45. The share price has gained 152.11% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $54.24 is greater than its 200-day moving average of $38.85. Shares of Juno Therapeutics have fallen roughly 17.99 percent in the past month and are up 134.32 percent year-to-date.
Access RDI's Juno Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=JUNO
On Thursday, shares in Seattle Genetics, Inc. recorded a trading volume of 1,412,294 shares, which was above the three months average volume of 1,024,645 shares. The stock ended the day 6.98% lower at 51.82. The stock is currently trading 27.34% below its 52-week high with a 52-week trading range of 45.31 - 71.32.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $58.85 is greater than its 200-day moving average of $56.11. Shares of Seattle Genetics have fallen roughly 9.41 percent in the past month and are down 1.8 percent year-to-date.
Access RDI's Seattle Genetics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SGEN
Our Actionable Research on Juno Therapeutics, Inc. (NASDAQ:JUNO) and Seattle Genetics, Inc. (NASDAQ:SGEN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
